Genmab GMAB

COP: GMAB | ISIN: DK0010272202   30/04/2025
1.390,00 DKK (+1,13%)
(+1,13%)   30/04/2025

28 april 2025 · Transactions in Connection with Share Buy-back Program · Persbericht

22 april 2025 · Transactions in Connection with Share Buy-back Program · Persbericht

15 april 2025 · Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 · Persbericht

14 april 2025 · Transactions in Connection with Share Buy-back Program · Persbericht

10 april 2025 · Genmab A/S Share Capital Reduction · Persbericht

7 april 2025 · Transactions In Connection with Share Buy-back Program · Persbericht

1 april 2025 · Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons · Persbericht

31 maart 2025 · TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer · Persbericht

31 maart 2025 · Transactions in connection with share buy-back program · Persbericht

27 maart 2025 · TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy · Persbericht

25 maart 2025 · Genmab Announces Initiation of Share Buy-Back Program · Persbericht

22 maart 2025 · Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. · Persbericht

17 maart 2025 · Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer · Persbericht

12 maart 2025 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

12 maart 2025 · Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab · Persbericht

10 maart 2025 · Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 · Persbericht

4 maart 2025 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

28 februari 2025 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

28 februari 2025 · Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab · Persbericht

25 februari 2025 · Capital Increase in Genmab as a Result of Employee Warrant Exercise · Persbericht

Mijn selecties